Kawasaki Disease

Table of Contents

  1. What Is Kawasaki Disease?
  2. How KD Damages Blood Vessels
  3. The Five Classic Diagnostic Criteria
  4. Incomplete Kawasaki Disease
  5. Coronary Artery Aneurysms: The Main Danger
  6. Making the Diagnosis
  7. Treatment: IVIG and Aspirin
  8. Long-Term Outlook and Monitoring
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What Is Kawasaki Disease?

Kawasaki Disease (KD) is an acute inflammatory illness that primarily affects young children, causing widespread inflammation of blood vessels — a condition called vasculitis. The vessels most at risk are the coronary arteries, the vessels that supply the heart muscle. Left untreated, Kawasaki Disease is now the most common cause of acquired heart disease in children in the United States and other developed countries, having surpassed rheumatic fever decades ago.

The illness was first described in 1967 by Japanese pediatrician Tomisaku Kawasaki, who published a case series of 50 children with a distinctive pattern of fever, rash, red eyes, swollen lymph nodes, and changes to the lips and hands that he called "acute febrile mucocutaneous lymph node syndrome." For years it was thought to be limited to Japan, but it is now recognized worldwide, with Japan having the highest incidence at roughly 265 cases per 100,000 children under age 5 and the United States reporting approximately 25 cases per 100,000 children in the same age group.

Who gets it? Kawasaki Disease overwhelmingly strikes young children:

Seasonal patterns have been noted — clusters occur in winter and spring — hinting at an infectious trigger, but after more than 50 years of research no single causative pathogen has been confirmed. Despite this uncertainty, the treatment is well-established, safe, and highly effective when given promptly.

Back to Table of Contents

How KD Damages Blood Vessels

Kawasaki Disease is best understood as a dysregulated inflammatory response to an infectious trigger. The current leading hypothesis is that one or more common respiratory pathogens ignite an abnormal immune reaction in genetically susceptible children, rather than the pathogen itself causing direct damage to vessel walls.

Key findings from decades of pathological research include:

Regardless of the inciting agent, the downstream immune cascade is better understood:

  1. Innate immune activation: Macrophages and dendritic cells are activated early, recognizing pathogen-associated molecular patterns.
  2. Cytokine storm: Massive release of pro-inflammatory cytokines — particularly IL-1β, IL-6, and TNF-α — drives the systemic inflammation that produces fever and the characteristic clinical features.
  3. Neutrophil infiltration of vessel walls: Neutrophils migrate into the walls of medium-sized arteries, including the coronary arteries. This is followed by macrophage and lymphocyte infiltration.
  4. Endothelial injury: The inflamed vessel wall weakens. The internal elastic lamina and medial smooth muscle are destroyed over days to weeks.
  5. Aneurysm formation: Without the structural integrity of the normal vessel wall, the coronary artery dilates under normal blood pressure, forming an aneurysm. In the most severe cases, these aneurysms can reach 8–10 mm in diameter or larger.

The inflammation is self-limited in most cases — the acute phase lasts about 10–14 days — but the structural damage to coronary arteries can persist for life. Thrombosis within a large or giant aneurysm can occur months or even decades later, causing a myocardial infarction in what is otherwise a healthy-appearing young adult.

Genetic factors also play a role. Studies in Japanese and European populations have identified susceptibility variants in genes regulating the inflammatory response (including FCGR2A, CASP3, and immune co-stimulatory pathways), which helps explain why only a fraction of exposed children develop KD.

Back to Table of Contents

The Five Classic Diagnostic Criteria

Kawasaki Disease is diagnosed clinically — there is no single blood test or imaging finding that confirms it. The classic definition requires fever lasting 5 or more days plus at least 4 of the following 5 features:

1. Fever (Required)

The fever is typically high — 39–40°C (102–104°F) or higher — and does not respond well to standard antipyretics. It persists for at least 5 days (often longer without treatment) and is the sine qua non of the diagnosis. No fever, no diagnosis.

2. Bilateral Conjunctival Injection

Both eyes become bloodshot, with prominent redness of the bulbar (white) conjunctiva. Crucially, the injection spares the limbus — the clear zone around the iris — a feature that helps distinguish KD from other causes of red eyes. There is no discharge, no crusting, and the eyes are not painful. Parents often describe it as "really red eyes without any goop."

3. Changes to the Lips and Oral Cavity

Three distinct oral findings appear:

4. Polymorphous Rash

The rash of Kawasaki Disease is variable — it can look maculopapular (flat and bumpy), morbilliform (measles-like), or urticarial (hive-like). Critically, it is never vesicular (blistering) — the presence of blisters should prompt a search for other diagnoses. An early and distinctive feature is a perineal rash (in the groin and perianal area) that appears in the first days of illness and often desquamates (peels) before the fingers and toes do, sometimes serving as an early clue.

5. Changes to the Extremities

Two phases occur:

6. Cervical Lymphadenopathy

Enlargement of one or more cervical (neck) lymph nodes to at least 1.5 cm in diameter. This is the least common of the five criteria, present in only about 50% of cases. It is often unilateral and can be dramatic, sometimes leading to an initial diagnosis of bacterial lymphadenitis and unnecessary antibiotic courses before KD is recognized.

Back to Table of Contents

Incomplete Kawasaki Disease

Not every child with Kawasaki Disease presents with all the textbook features. Incomplete KD (sometimes called atypical KD) is defined as fever lasting 5 or more days with fewer than 4 of the classic criteria but with laboratory or echocardiographic evidence of the disease process.

This matters enormously because the two groups at highest risk for incomplete presentation are also at highest risk for coronary artery aneurysms:

The American Heart Association algorithm for incomplete KD uses supporting laboratory criteria (CRP ≥ 3.0 mg/dL or ESR ≥ 40 mm/h) plus additional supplemental findings (albumin ≤ 3.0 g/dL, anemia for age, elevated ALT, platelet count ≥ 450,000/mm³ after day 7, WBC ≥ 15,000/mm³, urine WBC ≥ 10 per high-power field) to guide the decision to treat.

The guiding clinical principle is:

Never withhold IVIG from an infant with prolonged fever and some features of KD just because fewer than 4 criteria are present. The consequences of a missed diagnosis — a giant coronary aneurysm — are far worse than the very low risk of treating a child who may not have KD.

An echocardiogram showing coronary artery dilation (Z-score ≥ 2.5) in the setting of compatible illness is sufficient to confirm the diagnosis and initiate treatment regardless of how many classic criteria are met.

Back to Table of Contents

Coronary Artery Aneurysms: The Main Danger

The most serious complication of Kawasaki Disease — and the reason it must be treated urgently — is the development of coronary artery aneurysms (CAA). Without treatment, 15–25% of children with KD develop aneurysms. With timely IVIG given before day 10 of fever, that risk drops to approximately 3–5%.

How Aneurysms Are Classified

Aneurysm severity in KD is measured using the Z-score, which compares the measured coronary artery diameter to the expected diameter for a child of that body surface area:

Which Coronary Arteries Are Affected?

The right coronary artery (RCA) and the proximal left anterior descending (LAD) artery are most commonly affected. Aneurysms can also occur in the left main coronary artery and, less commonly, in other systemic arteries (axillary, iliac).

Why Giant Aneurysms Are Particularly Dangerous

Within a giant aneurysm, blood flow slows and becomes turbulent, creating ideal conditions for thrombosis (clot formation). A clot that forms inside a giant coronary aneurysm can occlude blood flow to the heart muscle, causing a myocardial infarction (heart attack). This can happen in the acute illness — or silently, years or even decades later. Young adults who suffered giant CAAs as infants with KD can present with their first MI in their 20s or 30s.

Echocardiographic Monitoring Schedule

All children with confirmed or suspected KD require echocardiography:

Back to Table of Contents

Making the Diagnosis

Diagnosing Kawasaki Disease is a clinical skill that depends on pattern recognition, because there is no single confirmatory test. A child with unexplained fever lasting 5 or more days should always prompt consideration of KD, especially if any classic features are present.

Laboratory Findings

Labs support rather than confirm the diagnosis. Typical findings include:

Echocardiography

Echocardiography is mandatory in all cases of confirmed or suspected KD. It can detect coronary artery dilation before aneurysms have fully formed, guides treatment decisions in incomplete KD, and establishes the baseline for long-term monitoring.

What KD Is Not

The differential diagnosis includes conditions that share some features: viral exanthems (measles, adenovirus, enterovirus), scarlet fever, staphylococcal scalded skin syndrome, toxic shock syndrome, drug hypersensitivity reactions (Stevens-Johnson syndrome), and systemic juvenile idiopathic arthritis. The combination of prolonged high fever, bilateral non-exudative conjunctivitis, oral changes, rash, and extremity changes — especially periungual desquamation — is characteristic of KD and not explained by these alternatives.

Back to Table of Contents

Treatment: IVIG and Aspirin

Treatment of Kawasaki Disease is time-sensitive. The goal is to suppress the inflammatory cascade before it damages the coronary arteries. The cornerstone of therapy is:

Intravenous Immunoglobulin (IVIG)

A single infusion of IVIG at 2 g/kg given over 10–12 hours is the primary treatment. When given before day 10 of fever onset, IVIG reduces the risk of coronary artery aneurysms from 15–25% down to 3–5%. The mechanism is not fully understood but likely involves modulation of inflammatory cytokine signaling and neutralization of the triggering antigen.

Aspirin

Aspirin plays a dual role in KD and is always used alongside IVIG:

Anticoagulation for Giant Aneurysms

Children with giant coronary aneurysms (≥ 8 mm) are at high risk of thrombosis and require dual therapy:

This is continued long-term under close cardiology supervision. Activity restrictions — particularly avoidance of contact sports — are recommended to reduce the risk of bleeding while anticoagulated.

Back to Table of Contents

Long-Term Outlook and Monitoring

For the vast majority of children with Kawasaki Disease who are diagnosed and treated promptly, the outlook is excellent. Fever resolves within 24–48 hours of IVIG. Energy returns. The rash fades. The desquamation resolves over several weeks. Most children recover completely with no lasting heart involvement.

However, a subset face a more complex long-term picture:

Children With No Coronary Involvement

Children whose echocardiograms remain normal through the 4–6 week follow-up can be safely discharged from cardiology follow-up. Their long-term cardiac risk is believed to be no higher than the general population. Low-dose aspirin is stopped after 6–8 weeks.

Children With Small or Medium Aneurysms

Many small aneurysms regress over 1–2 years as the vessel wall remodels. However, the vessel may retain abnormal stiffness and function even after the aneurysm appears to have resolved on echo. Regular cardiology follow-up is recommended.

Children With Giant Aneurysms

Giant aneurysms are the most serious long-term consequence. Key issues include:

Recurrence

KD can recur. The recurrence rate is approximately 3% in the United States and somewhat higher in Japan. Parents should be alert to the possibility of a second episode in a child who has had KD before, especially if another high-fever illness develops.

Emotional Impact on Families

A diagnosis of Kawasaki Disease is frightening for families. Parents often feel guilt about not recognizing the illness sooner, anxiety about long-term heart outcomes, and stress around frequent echocardiograms and medication management. Connecting with parent support communities and clear communication from the medical team about prognosis is essential for family wellbeing.

Back to Table of Contents

Key Research Papers

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16(3):178-222. PMID 6062087
  2. Newburger JW et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-71. PMID 15505111
  3. Newburger JW et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341-7. PMID 3523245
  4. McCrindle BW et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999. PMID 28356445
  5. Furusho K et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055-8. PMID 6149445
  6. Tremoulet AH et al. Aspirin dose and coronary artery outcomes in febrile phase Kawasaki Disease. Pediatrics. 2008;121(1):e93-9. PMID 18166538
  7. Salgado AP et al. Kawasaki disease in infants less than six months of age with coronary artery involvement. J Pediatr. 2011;159(4):604-8. PMID 21632044
  8. Rowley AH et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J Infect Dis. 2011;203(7):1021-30. PMID 21402548
  9. Egami K et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237-40. PMID 16887442
  10. Sundel RP et al. Corticosteroid treatment of Kawasaki disease: long-term follow-up. J Pediatr. 1995;126(4):577-80. PMID 7699538
  11. Sano T et al. Score for early risk stratification of coronary artery lesions and resistance to intravenous immunoglobulin in patients with Kawasaki disease: a nationwide prospective registry study. Lancet Child Adolesc Health. 2020;4(8):591-600. PMID 32593333
  12. Son MB, Newburger JW. Kawasaki Disease. Pediatr Rev. 2018;39(2):78-90. PMID 29437127

Search PubMed for more: Kawasaki Disease on PubMed

Back to Table of Contents

Connections

Back to Table of Contents